Literature DB >> 776831

Evidence for an extrinsic immunogen in effective ribosomal vaccines from Salmonella typhimurium.

P Hoops, N E Prather, J Berry, J M Ravel.   

Abstract

Previous work has indicated that ribosomes isolated from Salmonella typhimurium were highly immunogenic and afforded excellent protection against homologous challenge. Effective protection was obtained also when ribonucleic acid ( RNA) extracted from these ribosomes was used as a vaccine. In this investigation ribosomes prepared by another method and washed repeatedly in 1 M NH1Cl lost much of their prophylactic potency and yielded poorly protective RNA. The high-salt wash of the ribosomes was immunogenic. The RNA and the protein isolated from the salt wash of the ribosomes were effective vaccines. No intrinsic component of the ribosomes was removed by the NH4Cl wash, since the ability of both "crude" and "clean" ribosomes to function equally well in an in vitro protein synthesizing system was demonstrated. The presence of a component with toxic properties similar to those of endotoxin was found in active vaccines but not in weak ones. This was shown by the ability of effective vaccines to kill lead acetate-sensitized mice and to induce tolerance to endotoxin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 776831      PMCID: PMC420736          DOI: 10.1128/iai.13.4.1184-1192.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Initiation factor 3 requirement for the formation of initiation complexes with synthetic oligonucleotides.

Authors:  D P Suttle; M A Haralson; J M Ravel
Journal:  Biochem Biophys Res Commun       Date:  1973-03-17       Impact factor: 3.575

2.  Nonspecificity of the limulus amebocyte lysate test: positive reactions with polynucleotides and proteins.

Authors:  R J Elin; S M Wolff
Journal:  J Infect Dis       Date:  1973-09       Impact factor: 5.226

3.  Evidence for O antigens as the antigenic determinants in "ribosomal" vaccines prepared from Salmonella.

Authors:  T K Eisenstein
Journal:  Infect Immun       Date:  1975-08       Impact factor: 3.441

4.  Immunogenicity of ribosomal vaccines isolated from group A, type 14 Streptococcus pyogenes.

Authors:  W O Schalla; W Johnson
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

5.  Effect of nonspecific stimulation on the defense mechanisms of inbred mice.

Authors:  S Medina; S I Vas; H G Robson
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

6.  Immunity to Salmonella typhimurium infection: characterization of antigens in active protection by polyacrylamide gel electrophoresis.

Authors:  D P Houchens; G L Wright
Journal:  Infect Immun       Date:  1973-03       Impact factor: 3.441

7.  Efficacy of ribosomal preparations from Pseudomonas aeruginosa to protect against intravenous Pseudomonas challenge in mice.

Authors:  R L Smith; J A Wysocki; J N Bruun; S J De Courcy; W S Blakemore; S Mudd
Journal:  J Reticuloendothel Soc       Date:  1974-01

8.  Detection of delayed hypersensitivity in mice injected with ribonucleic acid-protein fractions of Salmonella typhimurium.

Authors:  R A Smith; N J Bigley
Journal:  Infect Immun       Date:  1972-09       Impact factor: 3.441

9.  Ribosomal vaccines. I. Immunogenicity of ribosomal fractions isolated from Salmonella typhimurium and Yersinia pestis.

Authors:  W Johnson
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

10.  Purification of immunogenically active ribonucleic acid preparations of Salmonella typhimurium: molecular-sieve and anion-exchange chromatography.

Authors:  M R Venneman
Journal:  Infect Immun       Date:  1972-03       Impact factor: 3.441

View more
  28 in total

1.  Evaluation of a ribosomal vaccine against pertussis.

Authors:  L H Field; C D Parker; C R Manclark; L J Berry
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

2.  Role of interferon in mice in protection against influenza A virus by bacterial ribosomes together with membranal glycoproteins of Klebsiella pneumoniae as adjuvant.

Authors:  D Robert; J P Quillon; B Ivanoff; Y Beaudry; R Fontanges; G Normier; A M Pinel; L D D'hinterland
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

3.  Immuno-stimulation by a ribosomal vaccine associated with a bacterial cell wall adjuvant in humans.

Authors:  F B Michel; L Dussourd D'Hinterland; J Bousquet; A M Pinel; G Normier
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

4.  Immunogenicity of ribosomes from enzymatically lysed Streptococcus pyogenes.

Authors:  B A Green; W Johnson
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

5.  Antigenic modification: its relation to protective host resistance in murine salmonellosis.

Authors:  N J Bigley; R A Smith; P Warren; W T Minahan; D P Kreps
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

6.  Role of endotoxin contamination in ribiosomal vaccines prepared from Salmonella typhimurium.

Authors:  M L Misfeldt; W Johnson
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

7.  Capsular serotypic specificity of the protection conferred on mice by Klebsiella pneumoniae ribosomal preparations.

Authors:  M Riottot; J M Fournier; J Pillot
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

8.  Comparative efficacy and toxicity of a ribosomal vaccine, acetone-killed cells, lipopolysaccharide, and a live cell vaccine prepared from Salmonella typhhimurium.

Authors:  C R Angerman; T K Eisenstein
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

9.  Variability of protection in inbred mice induced by a ribosomal vaccine prepared from Salmonella typhimurium.

Authors:  M L Misfeldt; W Johnson
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

10.  Humoral and cell-mediated responses to a ribosomal preparation from Streptococcus mutans.

Authors:  R L Gregory; I L Shechmeister
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.